Dr. Lal PathLabs Limited (IN:LALPATHLAB)
:LALPATHLAB
LALPATHLAB Stock Chart & Stats
₹1472.95
-₹106.10(-3.42%)
At close: 4:00 PM EST
₹1472.95
-₹106.10(-3.42%)
Day’s Range― - ―
52-Week Range₹1,187.50 - ₹1,771.30
Previous CloseN/A
Volume152.98K
Average Volume (3M)3.61K
Market Cap
₹220.15B
Enterprise Value₹213.47B
Total Cash (Recent Filing)₹13.02B
Total Debt (Recent Filing)₹2.55B
Price to Earnings (P/E)68.4
Beta0.62
Next Earnings
Apr 30, 2026EPS Estimate
7.4Next Dividend Ex-DateN/A
Dividend Yield0.89%
Share Statistics
EPS (TTM)6.70
Shares Outstanding167,555,020
10 Day Avg. Volume2,182
30 Day Avg. Volume3,614
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)9.21
Price to Sales (P/S)8.13
P/FCF Ratio38.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,577.00Price Target Upside7.06% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)30.6
Revenue Forecast (FY)₹27.36B
Bulls Say, Bears Say
Bulls Say
Strong Margins & Profit GrowthHigh gross (~60.8%) and net (~19.8%) margins combined with consistent revenue increases indicate durable operational efficiency. These margins support reinvestment, pricing flexibility, and ability to absorb reimbursement pressures, strengthening long-term cash conversion and profitability.
Robust Cash GenerationSignificant growth in operating and free cash flow demonstrates sustainable internal funding for capex, network expansion, and working capital. Strong cash conversion reduces reliance on external financing, providing strategic flexibility and resilience across multi-quarter cycles.
Conservative Balance SheetLow leverage and a strong equity ratio provide financial stability and capacity to fund growth or weather downturns. Conservative capital structure preserves strategic optionality for acquisitions, lab rollouts, or technology investments without materially increasing financial risk.
Bears Say
ROE Needs ImprovementA large equity base with only moderate ROE signals below-par capital efficiency versus peers. Persistently middling ROE can limit shareholder returns and suggests management must either deploy capital into higher-ROIC initiatives or improve operational leverage to boost long-term profitability.
Moderate Revenue Growth RateRevenue growth around 10–11% is steady but modest for a service provider in an expanding diagnostics market. Without faster top-line expansion or diversification, scaling margins and accelerating returns could be harder, potentially requiring strategic initiatives to open new geographies or service lines.
Revenue Tied To Test Volumes & MixDependence on sample volumes, test mix and network density exposes revenue and margins to demographic shifts, seasonality, and pricing pressure from B2B contracts. Sustaining growth requires ongoing investments in collection points, turnaround times and specialized services to protect long-term demand and pricing.
Dr. Lal PathLabs Limited News
LALPATHLAB FAQ
What was Dr. Lal PathLabs Limited’s price range in the past 12 months?
Dr. Lal PathLabs Limited lowest stock price was ₹1187.50 and its highest was ₹1771.30 in the past 12 months.
What is Dr. Lal PathLabs Limited’s market cap?
Dr. Lal PathLabs Limited’s market cap is ₹220.15B.
When is Dr. Lal PathLabs Limited’s upcoming earnings report date?
Dr. Lal PathLabs Limited’s upcoming earnings report date is Apr 30, 2026 which is in 30 days.
How were Dr. Lal PathLabs Limited’s earnings last quarter?
Dr. Lal PathLabs Limited released its earnings results on Jan 30, 2026. The company reported ₹6.7 earnings per share for the quarter, missing the consensus estimate of ₹7.625 by -₹0.925.
Is Dr. Lal PathLabs Limited overvalued?
According to Wall Street analysts Dr. Lal PathLabs Limited’s price is currently Undervalued.
Does Dr. Lal PathLabs Limited pay dividends?
Dr. Lal PathLabs Limited pays a Quarterly dividend of ₹7 which represents an annual dividend yield of 0.89%. See more information on Dr. Lal PathLabs Limited dividends here
What is Dr. Lal PathLabs Limited’s EPS estimate?
Dr. Lal PathLabs Limited’s EPS estimate is 7.4.
How many shares outstanding does Dr. Lal PathLabs Limited have?
Dr. Lal PathLabs Limited has 167,555,020 shares outstanding.
What happened to Dr. Lal PathLabs Limited’s price movement after its last earnings report?
Dr. Lal PathLabs Limited reported an EPS of ₹6.7 in its last earnings report, missing expectations of ₹7.625. Following the earnings report the stock price went up 0.946%.
Which hedge fund is a major shareholder of Dr. Lal PathLabs Limited?
Currently, no hedge funds are holding shares in IN:LALPATHLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company also offers lab staff training; technical; and lab management services. As of March 31, 2022, the company had 277 clinical laboratories, including National Reference Lab at Delhi and Regional Reference Lab at Kolkata; and 4,731 patient service centers and 10,599 pick-up points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India.
LALPATHLAB Stock 12 Month Forecast
Average Price Target
₹1,577.00
▲(7.06% Upside)
Technical Analysis
Jupiter Life Line Hospitals Ltd.
―
Krsnaa Diagnostics Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―